Adamis Pharmaceuticals

Adamis Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development, and sale of pharmaceutical, specialty biopharmaceutical, and other drug products. The company provides products in various therapeutic areas, including allergy, respiratory, opioid overdose, and erectile dysfunction markets. It offers the SYMJEPI Injection for the emergency treatment of allergic reactions. The company was founded in June 2006 and is headquartered in San Diego, CA.

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DMK Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development, and sale of pharmaceutical, specialty biopharmaceutical, and other drug products. The company provides products in various therapeutic areas, including allergy, respiratory, opioid overdose, and erectile dysfunction markets. It offers the SYMJEPI Injection for the emergency treatment of allergic reactions. The company was founded in June 2006 and is headquartered in San Diego, CA.

Company to begin trading under new ticker symbol “DMK” on September 8, 2023 Company to begin trading under new ticker symbol “DMK” on September 8, 2023

Adamis Pharmaceuticals Changes Name to DMK Pharmaceuticals to Reflect New Strategic Focus

SAN DIEGO, Aug. 21, 2023 (GLOBE NEWSWIRE) --  Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2023, and provided an update on recent corporate developments.

Adamis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

SAN DIEGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the closing of its public offering of 5,930,000 units, with each unit consisting of one share of common stock (or pre-funded warrant in lieu thereof) and one warrant to purchase one share of common stock. Each unit was sold at a public offering price of $1.35. The common warrants are immediately exercisable at a price of $1.35 per share and expire five years from the date of issuance. The shares of common stock (or pre-funded warrants in lieu thereof) and accompanying common warrants were only purchasable together in this offering, but were issued separately and immediately separable upon issuance.

Adamis Pharmaceuticals Announces Closing of $8.0 Million Public Offering

SAN DIEGO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the pricing of its public offering of 5,930,000 units at a public offering price of $1.35 per unit. Each unit consists of one share of common stock (or a prefunded warrant in lieu thereof) and one warrant to purchase one share of common stock. The common warrants will be immediately exercisable at an exercise price of $1.35 per share and will expire five years from the date of issuance. The shares of common stock (or pre-funded warrants in lieu thereof) and accompanying common warrants can only be purchased together in this offering, but will be issued separately and will be immediately separable upon issuance.

Adamis Pharmaceuticals Announces Pricing of $8.0 Million Public Offering

SAN DIEGO, July 28, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the Company has committed to fund an unrestricted research grant to the Leiden University Medical Center (LUMC) Anesthesia and Pain Research Unit. The funding will support the work of Albert Dahan, MD, PhD, a world expert on opioid-induced respiratory depression (opioid overdose) and professor of anesthesiology at the University. Dr. Dahan has been working with the FDA since 2020 to understand better methods of reversing fentanyl overdoses.

Adamis Pharmaceuticals to Fund ZIMHI® Clinical Study with University of Leiden Opioid Expert

SAN DIEGO, June 26, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced that its wholly owned subsidiary DMK Pharmaceuticals Corporation was the recipient of a grant from the National Institute on Alcohol Abuse And Alcoholism (NIAAA) of the National Institutes of Health (NIH) to support the development of a novel bifunctional small molecule for the treatment of Alcohol Use Disorder (AUD) (#R41AA030226).

Adamis Pharmaceuticals Announces NIH Grant Funding for the Treatment of Alcohol Use Disorder

SAN DIEGO, May 25, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced the closing of its merger with DMK Pharmaceuticals Corporation.

Adamis Pharmaceuticals Announces Closing of the Merger with DMK Pharmaceuticals

SAN DIEGO, May 19, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, announced today that it will effect a 1-for-70 reverse stock split of its common stock that will become effective on May 22, 2023, at 12:01 a.m., Eastern Time. Adamis' common stock will continue to trade on The Nasdaq Capital Market ("Nasdaq") under the symbol “ADMP” and will begin trading on a split-adjusted basis when the market opens on May 22, 2023.

Adamis Pharmaceuticals Announces Reverse Stock Split

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP ) Q1 2023 Earnings Conference Call May 15, 2023 5:00 PM ET Company Participants Robert Uhl - MD, ICR Westwicke David Marguglio - CEO David Benedicto - CFO Eboo Versi - CEO, DMK Pharmaceuticals Conference Call Participants Operator Greetings, and welcome to Adamis Pharmaceuticals First Quarter 2023 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

Adamis Pharmaceuticals Corporation (ADMP) Q1 2023 Earnings Call Transcript

Management to host webcast/conference call today at 2:00 p.m. PT / 5:00 p.m. ET Management to host webcast/conference call today at 2:00 p.m. PT / 5:00 p.m. ET

Adamis Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

SAN DIEGO, May 08, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including opioid overdose, allergy, respiratory and inflammatory disease, today announced that it will host an investor conference call on Monday, May 15, 2023 at 2:00 p.m. Pacific Time to discuss its financial and operating results for the first quarter 2023 as well as provide a corporate update, which may include an update concerning the results of the company's special meeting of stockholders scheduled to be held on May 15, 2023 at 10:00 a.m. Pacific Time as well as the proposals to be considered and acted upon at the meeting. The company's first quarter 2023 financial results news release is expected to be available after 1:00 p.m. Pacific Time on May 15, 2023, and on its website.

Adamis Pharmaceuticals Schedules First Quarter 2023 Financial Results Conference Call and Corporate Update

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP ) Q4 2022 Results Conference Call March 16, 2023 5:00 PM ET Company Participants Robert Uhl - MD, ICR Westwicke David Marguglio - CEO David Benedicto - CFO Dr. Eboo Versi - CEO, DMK Pharmaceuticals Conference Call Participants Operator Greetings, and welcome to the Adamis Pharmaceuticals Full Year 2022 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

Adamis Pharmaceuticals Corporation (ADMP) Q4 2022 Earnings Call Transcript

Management to host webcast/conference call today at 2 p.m. PT / 5 p.m. ET Management to host webcast/conference call today at 2 p.m. PT / 5 p.m. ET

Adamis Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Corporate Update

SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including opioid overdose, allergy, respiratory and inflammatory disease, today announced that it will host an investor conference call on Thursday, March 16, 2023 at 2:00 p.m. PT to discuss its financial and operating results for the fourth quarter and full year 2022 as well as provide a corporate update. The company's fourth quarter and full year 2022 financial results news release is expected to be available after 1 p.m. PT on March 16, 2023, and on its website .

Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2022 Financial Results Conference Call and Corporate Update

SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including opioid overdose, allergy, respiratory and inflammatory disease, today announced it has entered into a securities purchase agreement with a single, healthcare-focused institutional investor for the purchase and sale of 16,500,000 shares of its common stock and pre-funded warrants to purchase up to 7,500,000 shares of common stock, together with warrants to purchase up to 48,000,000 shares of common stock, at a combined purchase price of $0.125 per share (and $0.1249 per pre-funded warrant) and accompanying warrants, pursuant to a registered direct offering. The warrants will have an exercise price of $0.138 per share, will be initially exercisable beginning six months following the date of issuance and will expire five years and six months from the date of issuance.

Adamis Pharmaceuticals Announces $3.0 Million Registered Direct Offering

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Adamis Pharmaceuticals Corporation (the “Company”) (NasdaqCM: ADMP) with DMK Pharmaceuticals, Corp. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company.

ADAMIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adamis Pharmaceuticals Corporation - ADMP

NEW YORK , March 1, 2023 /PRNewswire/ -- Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Adamis Pharmaceuticals Corp. (NASDAQ: ADMP), relating to its proposed merger with DMK Pharmaceuticals Corp. Click here for more information: https://www.monteverdelaw.com/case/adamis-pharmaceuticals-corp. It is free and there is no cost or obligation to you.

SHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Adamis Pharmaceuticals Corp. - ADMP

It's an unusual day for Adamis Pharmaceuticals (NASDAQ: ADMP ) stock traders, to say the least. That's because the company recently announced its intent to acquire DMK Pharmaceuticals.

Adamis Pharmaceuticals (ADMP) Stock Wavers on Merger News

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) and DMK Pharmaceuticals, Corp. is fair to Adamis shareholders. Halper Sadeh encourages Adamis shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.

ADMP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Adamis Pharmaceuticals Corporation Is Fair to Shareholders

SAN DIEGO and SOMERVILLE, N.J., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including opioid overdose, allergy, respiratory and inflammatory disease, and DMK Pharmaceuticals, Corp., a private, clinical-stage biotechnology company at the forefront of endorphin-inspired drug design focused on developing novel treatments for opioid use disorder (OUD) and other neuro-based diseases, today announced that the companies have entered into an Agreement and Plan of Merger and Reorganization (the “Agreement”). Pursuant to the Agreement, Adamis will acquire DMK, including its library of approximately 750 small molecule neuropeptide analogues and on-going government funding for its development programs.

Adamis Pharmaceuticals and DMK Pharmaceuticals Announce Agreement and Plan of Merger

SAN DIEGO, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including opioid overdose, allergy, respiratory and inflammatory disease, today announced that the Nasdaq Hearings Panel (the “Panel”) has granted the Company's request for continued listing on Nasdaq, pursuant to an extension through June 26, 2023 to evidence compliance with the $1.00 bid price requirement and its continued compliance with all other applicable criteria for continued listing on the Nasdaq Capital Market (the “Compliance Period”).

Nasdaq Grants Adamis Pharmaceuticals' Request for Extension to Comply with Continued Listing Requirements

Surrozen

VEON

Use these tips for diversifying your investments in penny stocks The post How to Diversify Your Penny Stock Investments  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

How to Diversify Your Penny Stock Investments

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP ) Q3 2022 Earnings Conference Call November 14, 2022 5:00 PM ET Company Participants Robert Uhl - Westwicke Partners David Marguglio - Co-Founder, CEO, President & Director David Benedicto - CFO Conference Call Participants Operator Good afternoon, ladies and gentlemen, and welcome to the Adamis Pharmaceuticals' Third Quarter 2020 Financial Results Conference Call. [Operator Instructions].

Adamis Pharmaceuticals Corporation (ADMP) Q3 2022 Earnings Call Transcript

Adamis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

AnPac Bio-Medical Science Co

Borqs Technologies

Clever Leaves Holdings Inc

Cosmos Holdings

Corbus Pharmaceuticals Holdings

Altamira Therapeutics Ltd

Matinas BioPharma Hlds

Nutex Health Inc

Oblong

Penny stocks to watch under $1 right now. The post 10 Top Penny Stocks To Buy For Uner $1 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

News for Adamis Pharmaceuticals Stock (ADMP)